

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
AND
PROPOSED ADOPTION OF
THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION**

The Board (the “**Board**”) of directors of Essex Bio-Technology Limited (the “**Company**”) announces that it proposed to amend the existing articles of association of the Company (the “**Articles**”) and to adopt the amended and restated articles of association of the Company incorporating the proposed amendments (the “**Amended and Restated Articles of Association**”) for the purpose of, among others, bringing the Articles in line with (i) the latest regulatory requirements in relation to the expanded paperless listing regime and electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) which took effect on 31 December 2023; (ii) amendments made to the Listing Rules relating to treasury shares which took effect on 11 June 2024; and (iii) amendments made to the Listing Rules relating to the further expanded paperless listing regime, some amendments of which took effect from 10 February 2025 with the remaining amendments expected to gradually come into effect at the end of 2025 and thereafter. Other amendments to the Articles are also made for corresponding as well as housekeeping changes.

The proposed adoption of the Amended and Restated Articles of Association is subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting of the Company (the “**AGM**”) and will become effective upon the approval by the Shareholders at the AGM. A circular containing, among other things, particulars relating to the proposed amendments to the Articles brought about by the adoption of the Amended and Restated Articles of Association together with a notice convening the AGM will be despatched to the Shareholders on 7 April 2025.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 1 April 2025

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Ms. Yeow Mee Mooi and Mr. Yan Man Sing Frankie.